生物技术公司Relay Therapeutics近日披露其创新疗法在经多线治疗的CDK4/6抑制剂经治乳腺癌患者群体中取得突破性数据。临床研究显示，针对这类预后极差的晚期患者，实验性治疗方案实现了44%的客观缓解率，为现有治疗选择有限的人群带来新的希望。
该数据来源于一项针对既往接受过中位三线以上系统性治疗的转移性乳腺癌患者的研究。所有入组患者均曾使用CDK4/6抑制剂但出现疾病进展，属于临床治疗中的难点人群。44%的客观缓解率显著超越了现有标准疗法在该人群中的历史数据，暗示其可能成为后线治疗的重要突破。
研究人员指出，这一结果验证了公司专有蛋白质运动学平台在药物发现中的价值。通过精准靶向蛋白质动态构象变化开发的新一代抑制剂，展现出对耐药机制的独特克服能力。后续将开展更大规模临床试验以确认疗效，并探索与其它靶向药物的联合应用潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.